Red Flags

BBIO — BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, w

**THE CORE CONCERN**

BridgeBio’s Beneish M-Score of 8.22 breaches the −1.78 manipulation threshold by a wide margin, placing the company among observations the model historically classified as earnings manipulators. The score is driven by two inputs that stand out even after growth adjustments: DSRI of 13.05, indicating accounts receivable expanded more than twelve times faster than revenue, and SGI of 2.26, reflecting 126 % year-on-year revenue growth. These ratios produced the maximum 35-point contribution to the M-Score. The Altman Z-Score of −2.19 simultaneously sits inside the distress zone, while short interest at 18.8 % of float registers elevated skepticism among market participants. Revenue has expanded from $0.1 B to $0.5 B across the measured periods at an 86.3 % CAGR, yet the combination of extreme accrual and receivables metrics with a sub-1.81 Z-Score forms the central quantitative tension.

**HISTORICAL PRECEDENT**

The pattern most closely tracks the FY1997–1998 Enron profile that the Beneish model flagged three years before collapse. Enron exhibited an M-Score well above the threshold, propelled by rapid reported revenue growth and disproportionate receivables increases that later proved to be premature or fictitious recognition. While BridgeBio operates in biotechnology rather than energy trading, the same two variables—SGI and DSRI—account for the bulk of the score elevation in both cases.

**WHAT TO VERIFY**

Investigators should examine three items in the 10-K or 10-Q. First, the aging schedule and concentration of accounts receivable by contract size and customer to determine whether the DSRI spike coincides with a small number of large, long-dated milestone or licensing agreements. Second, the precise revenue-recognition policy for collaboration and royalty revenue, specifically the percentage satisfied over time versus at a point in time and any changes in estimates during the high-growth quarters. Third, the reconciliation of net loss to operating cash flow, isolating the working-capital components that produced the observed accruals ratio of 0.000 despite the M-Score elevation.

**COUNTERARGUMENTS**

High-growth biotechnology companies routinely generate forensic signals that do not reflect manipulation. BridgeBio’s revenue CAGR of 86.3 % over three years is consistent with the commercialization phase of multiple programs; such expansion commonly inflates SGI and can temporarily elevate DSRI when enterprise or licensing contracts carry extended payment terms. The company remains pre-profitability, a stage in which negative operating cash flow and balance-sheet expansion are expected while R&D and sales infrastructure are funded. The accruals ratio of 0.000 lies well below the 0.05 threshold, and the five-year cumulative net-income-to-operating-cash-flow divergence is zero, indicating that reported earnings have not systematically outpaced cash generation. These factors suggest the M-Score and Z-Score readings may be artifacts of legitimate scaling rather than accounting distortion, though the magnitude of the DSRI deviation still warrants direct verification against contract terms and collection history.

BCRX — BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and

1. THE CORE CONCERN

The most anomalous signal is the Beneish M-Score of 256.21, which lies far closer to zero than the −1.78 manipulation threshold. On a scale where less-negative values indicate higher statistical likelihood of earnings manipulation, this reading exceeds the levels that flagged Enron in fiscal 1997–1998. The Altman Z-Score of −2.04 simultaneously places the firm in the distress zone below 1.81. Offsetting these are an accruals ratio of 0.000, zero instances of positive net income paired with negative operating cash flow, and flat cumulative NI–OCF divergence. Revenue has expanded from $0.2 B to $0.5 B over the measured period, producing a 42.1 % CAGR; such rapid top-line growth can mechanically inflate several Beneish components (SGI, DSRI) without implying accounting distortion.

2. HISTORICAL PRECEDENT

The combination of an extreme M-Score breach and a sub-1.81 Z-Score mirrors the profile observed at Enron three years prior to its 2001 collapse. In that case, the model captured accelerating revenue recognition and off-balance-sheet financing before cash-flow shortfalls became visible. BCRX’s profile differs in that operating cash flow has remained aligned with reported losses and accruals have not risen, reducing the direct parallel to classic receivables or channel-stuffing schemes.

3. WHAT TO VERIFY

Investigators should examine three items in the 10-K/10-Q. First, the composition of the $0.5 B revenue line—specifically the proportion recognized under collaboration or licensing agreements versus product sales—and whether any milestones were front-loaded. Second, the capitalization policy for clinical-trial and manufacturing scale-up costs, including the amortization schedule applied once products reach commercial stage. Third, the reconciliation between the reported cash-burn rate and the disclosed cash-runway projection, with particular attention to working-capital changes tied to inventory build or deferred revenue.

4. COUNTERARGUMENTS

Rapid revenue growth at a pre-profitability biotechnology company routinely produces M-Score and Z-Score readings outside normal bounds because the underlying ratios were calibrated on mature industrial firms. Investment-phase economics—R&D spend, sales-force expansion, and milestone timing—can generate negative cash flow and low Z-Scores without earnings manipulation. The zero accruals ratio and absence of NI–OCF divergence provide quantitative evidence that reported losses are not being masked by non-cash adjustments. Short interest at 16 % of float may simply reflect sector-wide skepticism toward clinical-stage burn rates rather than specific accounting concerns. These factors indicate that the forensic flags warrant examination of growth quality and cash deployment, but do not by themselves establish manipulation.